ASTEC LIFESCIENCES LIMITED - 533138 - Corporate Action-Board approves Dividend
The Board of Directors has recommended Final Dividend of 15% (Fifteen per cent) on the Equity Share Capital of the Company, i.e., Rs.1.50 (Rupee One and Paise Fifty ) per Equity Share of Face Value of Rs.10/- (Rupees Ten Only) each for the Financial Year ended 31st March, 2023, subject to approval of the Shareholders at the ensuing 29th (Twenty Ninth) Annual General Meeting of the Company. ASTEC LIFESCIENCES LIMITED - 533138 - AUDITED FINANCIAL RESULTS (STANDALONE AND CONSOLIDATED) FOR THE QUARTER AND FINANCIAL YEAR ENDED 31ST MARCH, 2023
Kindly find attached the Audited Financial Results (Standalone & Consolidated) as per Indian Accounting Standards) for the Quarter and Financial Year ended 31st March, 2023. ASTEC LIFESCIENCES LIMITED - 533138 - Board Meeting Outcome for Outcome Of The Board Meeting
Kindly find attached the outcome of the Board Meeting held on 2nd May, 2023. ASTEC LIFESCIENCES LIMITED - 533138 - Board Meeting Intimation for Intimation Of Board Meeting As Per Regulation 29 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
ASTEC LIFESCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/05/2023 ,inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results for the Quarter and Financial Year ended 31st March, 2023 after these results are reviewed by the Audit Committee and to consider recommendation of Final Dividend, if any, on the Equity Shares of the Company for the Financial Year ended 31st March, 2023. ASTEC LIFESCIENCES LIMITED - 533138 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company ASTEC LIFESCIENCES LIMITED 2 CIN NO. L99999MH1994PLC076236 3 Report filed for FY 2022-2023 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* 2022-23, 23-24 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)2021-22, 22-23 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-TEJASHREE PRADHANDesignation :-COMPANY SECRETARY AND COMPLIANCE OFFICER Name of the Chief Financial Officer :- MADHUR GUNDECHA Designation : -CHIEF FINANCIAL OFFICER Date: 18/04/2023 ASTEC LIFESCIENCES LIMITED - 533138 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyASTEC LIFESCIENCES LIMITED 2CIN NO.L99999MH1994PLC076236 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 55.90 4Highest Credit Rating during the previous FY AA- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Tejashree Pradhan Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: Madhur Gundecha Designation: Chief Financial Officer EmailId: [email protected] Date: 12/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Astec LifeSciences launches its R&D centre in Maharashtra's Rabale
Astec LifeSciences, a subsidiary of Godrej Agrovet (GAVL), on Tuesday launched its Research and Development (R&D) centre in Rabale, Maharashtra. The facility 'Adi Godrej Centre for Chemical Research and Development' will focus on innovation and developing sustainable and safe solutions for people and the environment and providing services to innovator companies in the contract development & manufacturing space, the company said in a statement. "The CDMO (Contract Development and Manufacturing Organisation) market for chemicals in India is expected to grow at a CAGR of 12 per cent as against the global rate of 10 per cent. This underlines the potential in this sector, and our new facility will enable us to expand our offerings specifically in CDMO space," Astec LifeSciences Chief Executive Officer Anurag Roy said. It will also make the company a partner of choice through its improved ability of providing end-to-end solutions to customers from the R&D stage to development to ASTEC LIFESCIENCES LIMITED - 533138 - Compliance Certificate Under Regulation 7(3) Read With Regulation 7(2) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Financial Year Ended 31St March, 2023
Please find enclosed herewith, Compliance Certificate under Regulation 7(3) read with Regulation 7(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Financial Year ended March 31, 2023. ASTEC LIFESCIENCES LIMITED - 533138 - Intimation With Respect To Launch Of A New Advanced Research And Development (R&D) Center In Rabale, Maharashtra, Named As 'Adi Godrej Center For Chemical Research And Development'
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that, we have launched today, a new advanced Research and Development (R&D) Center in Rabale, Maharashtra, named as 'Adi Godrej Center for Chemical Research and Development'. The said facility will focus on leading-edge innovation and developing sustainable and safe solutions for people and the environment and providing services to innovator companies in Contract Development & Manufacturing space.